Ho, Ping-Chih <br/><br/>
Immune-based antitumor effects of BRAF inhibitors rely on signaling by CD40L and IFNγ.  [electronic resource] 

 -  Cancer research  Jun 2014 
 - 3205-17 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural 
<br/><br/><label>ISSN: </label>1538-7445 
<br/><br/><label>Standard No.: </label>10.1158/0008-5472.CAN-13-3461  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antigen-Presenting Cells--drug effects<br/>Antineoplastic Agents--pharmacology<br/>CD4-Positive T-Lymphocytes--drug effects<br/>CD40 Ligand--physiology<br/>Drug Screening Assays, Antitumor<br/>Indoles--pharmacology<br/>Interferon-gamma--physiology<br/>Macrophages--drug effects<br/>Melanoma, Experimental--drug therapy<br/>Mice<br/>Mice, Transgenic<br/>Mutation, Missense<br/>Proto-Oncogene Proteins B-raf--antagonists & inhibitors<br/>Signal Transduction<br/>Skin Neoplasms--drug therapy<br/>Sulfonamides--pharmacology<br/>Tumor Microenvironment--immunology